OptiNose
A publicly traded, global specialty pharmaceutical company focused on serving the needs of patients cared for by ENT and Allergy specialists.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
* | $330m Valuation: $330m | Acquisition | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (91 %) | 390 % | 42 % | 52 % | 2 % | (7 %) | 10 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (1371 %) | (276 %) | (178 %) | (89 %) | (73 %) | (28 %) | (2 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1510 %) | (318 %) | (203 %) | (110 %) | (98 %) | (50 %) | (28 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 143 % | 60 % | 48 % | 34 % | 20 % | 7 % | 5 % |
Source: Company filings or news article
Related Content
Optinose is a specialty pharmaceutical company dedicated to developing and commercializing innovative products for patients with diseases managed by ear, nose, and throat (ENT) and allergy specialists. The company operates in the healthcare sector, focusing on improving the quality of life for patients through advanced medical solutions. Optinose serves a niche market of ENT and allergy specialists, providing them with cutting-edge treatments that aim to become the standard of care in their fields.
The business model of Optinose revolves around research and development, followed by the commercialization of its pharmaceutical products. Revenue is generated through the sale of these specialized medications to healthcare providers and institutions. The company invests heavily in clinical trials and regulatory approvals to ensure the efficacy and safety of its products.
Optinose's market includes healthcare providers, particularly those specializing in ENT and allergy treatments. By focusing on this specific segment, the company aims to address unmet medical needs and offer solutions that significantly improve patient outcomes.
Keywords: specialty pharmaceutical, ENT, allergy, innovative products, patient quality of life, healthcare, clinical trials, regulatory approvals, niche market, medical solutions.